Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepenofovir Fumarate in Healthy Volunteers
NCT04277897Phase 1Unknown
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co., Ltd.
- Start
- Mar 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of Hepenofovir in Chronic Hepatitis B (CHB) (5 arms), sponsored by Xi'an Xintong Pharmaceutical Research Co., Ltd. Primary endpoint: Safety measured by adverse events up to 13 Days. Status: unknown.
02
Drugs
Hepenofovir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04277897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04277897.